Valuation: BioNTech SE

Capitalization 2.53TCr 2.96TCr 2.35TCr 2.2TCr 4.09TCr 2,71200Cr 4.38TCr 27TCr 11TCr 1,28200Cr 11TCr 11TCr 4,68200Cr P/E ratio 2025 *
-29.8x
P/E ratio 2026 * -40.5x
Enterprise value 1.47TCr 1.72TCr 1.36TCr 1.28TCr 2.37TCr 1,57400Cr 2.54TCr 16TCr 6.19TCr 74TCr 6.44TCr 6.31TCr 2,71700Cr EV / Sales 2025 *
5.47x
EV / Sales 2026 * 5.74x
Free-Float
86.48%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.42%
1 week+8.14%
Current month+23.95%
1 month+27.57%
3 months+10.39%
6 months+8.35%
Current year+23.95%
More quotes
1 week 105.1
Extreme 105.1
118.46
1 month 91.91
Extreme 91.91
118.46
Current year 95.85
Extreme 95.85
118.46
1 year 81.2
Extreme 81.2
126.77
3 years 76.53
Extreme 76.5301
147.66
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO 53 01/09/2014
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 64 01/01/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+11.78%+8.14%+0.64%-17.36% 2.65TCr
+1.49%-0.14%+9.71%+95.78% 4.92TCr
-0.91%-4.69%+77.60%+1.08% 4.25TCr
-4.40%-4.37%+103.67%+648.66% 3.49TCr
+2.03%-2.10%+115.16%-45.15% 1.97TCr
+4.50%-2.70%+38.28%-23.80% 1.93TCr
-0.09%-7.62%+94.04%+125.74% 1.39TCr
-4.61%-12.22%+157.32% - 1.32TCr
+4.92%-4.53%-23.76%+283.83% 1.24TCr
Average +0.28%-3.52%+63.63%+133.60% 2.57TCr
Weighted average by Cap. -0.02%-2.55%+58.32%+141.21%
See all sector performances

Financials

2025 *2026 *
Net sales 268.67Cr 314.24Cr 249.4Cr 233.91Cr 433.94Cr 29TCr 464.66Cr 2.86TCr 1.13TCr 14TCr 1.18TCr 1.15TCr 50TCr 258.58Cr 302.44Cr 240.04Cr 225.12Cr 417.65Cr 28TCr 447.22Cr 2.75TCr 1.09TCr 13TCr 1.13TCr 1.11TCr 48TCr
Net income -88Cr -102.57Cr -81Cr -76Cr -141.64Cr -9.39TCr -151.66Cr -934.23Cr -369.7Cr -4.44TCr -384.62Cr -376.75Cr -16TCr -53Cr -62Cr -49Cr -46Cr -86Cr -5.67TCr -92Cr -564.28Cr -223.3Cr -2.68TCr -232.31Cr -227.56Cr -9.8TCr
Net Debt -1.06TCr -1.24TCr -986.39Cr -925.1Cr -1.72TCr -1,13800Cr -1.84TCr -11TCr -4.48TCr -54TCr -4.66TCr -4.57TCr -1,96500Cr -1.05TCr -1.22TCr -971.1Cr -910.75Cr -1.69TCr -1,12100Cr -1.81TCr -11TCr -4.41TCr -53TCr -4.59TCr -4.49TCr -1,93500Cr
More financial data * Estimated data
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
6,772
More about the company
Date Price Change Volume
21/26/21 118.00 $ +11.78% 21,11,433
20/26/20 105.56 $ -3.16% 9,46,733
16/26/16 109.00 $ +2.76% 11,92,471
15/26/15 106.07 $ -2.80% 6,75,903
14/26/14 109.12 $ +1.80% 14,09,933

Delayed Quote Nasdaq, January 22, 2026 at 02:30 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
100.89EUR
Average target price
119.16EUR
Spread / Average Target
+18.11%
Consensus

Quarterly revenue - Rate of surprise